PMID- 29164666
OWN - NLM
STAT- MEDLINE
DCOM- 20190816
LR  - 20201209
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 45
IP  - 5
DP  - 2018 May
TI  - Expression of DCUN1D1 in laryngeal squamous cell carcinoma and its inhibiting 
      effect on TU-177 cells after interfered by RNA.
PG  - 461-466
LID - 10.1111/1440-1681.12893 [doi]
AB  - Expression of DCUN1D1 in laryngeal squamous cell carcinoma (LSCC) and its 
      inhibition by small interfering RNA (siRNA) target in the TU-177 cells was 
      investigated. Immunohistochemistry was used to detect the expression level of 
      DCUN1D1 in LSCC tissue in 140 cases and to analyze its relationship with clinical 
      pathological characteristics. siRNA expression plasmid targeting DCUN1D1 was 
      constructed and transferred into TU-177 cells. The effect of siRNA target DCUN1D1 
      gene silencing on proliferation, invasion and migration of TU-177 cells were 
      observed by MTS assay and Transwell experiment. The expression levels of focal 
      adhesion kinase (FAK) and matrix metalloproteinase-2(MMP-2) were detected by 
      western blot. Expression level of DCUN1D1 protein increased significantly in 
      T3 + T4, N+, and III + IV stages of LSCC patients (P < .05). After DCUN1D1 was 
      targeted by siRNA, the DCUN1D1 protein level decreased 67% in siRNA-3 group, 
      where average absorbance value was lower than the control and blank group with 
      significant difference(F = 6.076, P < .05) in MTS assay, meantime migration, and 
      invasion cells in each vision were the same (F = 19.851, F = 25.454, P < .01) in 
      the Transwell experiment. The expression level of FAK and MMP-2 was significantly 
      down-regulated in siRNA-3 group (F = 28.896, F = 40.240, P < .01). DCUN1D1 is 
      associated with progression and prognosis of LSCC. After siRNA based target on 
      DCUN1D1, TU-177 cells growth was inhibited and invasion of malignant tumour was 
      diminished by reducing the expression of FAK and MMP-2. DCUN1D1 is could become a 
      potential new target for the treatment of LSCC.
CI  - (c) 2017 John Wiley & Sons Australia, Ltd.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Shuang, Yu
AU  - Shuang Y
AUID- ORCID: 0000-0002-0750-3490
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Zhou, Xuan
AU  - Zhou X
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology, Key Laboratory of 
      Cancer Prevention and Therapy, National Clinical Research Center of Cancer, 
      Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital, 
      Tianjin, China.
FAU - Huang, Yongwang
AU  - Huang Y
AD  - Department of Otorhinolaryngology Head and Neck Surgery, The Second Hospital of 
      Tianjin Medical University, Tianjin, China.
FAU - Zhang, Lun
AU  - Zhang L
AD  - Department of Otorhinolaryngology and Maxillofacial Oncology, Key Laboratory of 
      Cancer Prevention and Therapy, National Clinical Research Center of Cancer, 
      Tianjin Cancer Institute, Tianjin Medical University Cancer Institute & Hospital, 
      Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171221
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (DCUN1D1 protein, human)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Proteins)
RN  - 0 (RNA, Small Interfering)
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/*genetics
MH  - *Gene Silencing
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins
MH  - Kaplan-Meier Estimate
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Proteins/*genetics/*metabolism
MH  - RNA, Small Interfering/*genetics
OTO - NOTNLM
OT  - RNA
OT  - focal adhesion kinase
OT  - laryngeal squamous cell carcinoma
OT  - matrix metalloproteinase-2
OT  - tumour gene
EDAT- 2017/11/23 06:00
MHDA- 2019/08/17 06:00
CRDT- 2017/11/23 06:00
PHST- 2017/06/01 00:00 [received]
PHST- 2017/11/05 00:00 [revised]
PHST- 2017/11/08 00:00 [accepted]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2019/08/17 06:00 [medline]
PHST- 2017/11/23 06:00 [entrez]
AID - 10.1111/1440-1681.12893 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2018 May;45(5):461-466. doi: 10.1111/1440-1681.12893. 
      Epub 2017 Dec 21.